SIGA Technologies will organize a commercial update call in November
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) – SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call for provide an update at 4:30 p.m. ET on Thursday, November 4e, 2021. Dr Phil Gomez, Managing Director, Daniel Luckshire, CFO and Dennis Hruby, Scientific Director, will participate in the call.
A live webcast of the call will also be available on the Company’s website at www.siga.com under the “Events and Presentations” tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes before the scheduled start time.
Participants can access the call by dialing 1-877-425-9470 for national calls or 1-201-389-0878 for international calls.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using conference ID: 13722063. Archived webcast will be available in the Events and Presentations section of the Company’s website.
ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the food safety market. Health security includes countermeasures to biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies against emerging infectious diseases and health preparedness. Our flagship product is TPOXX®, also known as tecovirimat and ST-246®, an antiviral drug administered by mouth and IV for the treatment of human smallpox caused by variola virus. TPOXX® is a new small molecule drug and the US government maintains a stockpile of TPOXX® for the treatment of smallpox. Over the past decade, the U.S. government has purchased or currently has orders for approximately $ 705 million from TPOXX® for national preparation. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253.
For more information on SIGA, please visit www.siga.com.
ABOUT LA VAROCHEI
Smallpox is a contagious, disfiguring and often fatal disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide in 1980, the result of an unprecedented global vaccination campaign. Smallpox virus samples were kept for research. This has led to fears that smallpox could one day be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of side effects from the current vaccine is too high to justify routine immunization of people at low risk of exposure to the smallpox virus.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements contained in this press release, are set out in the documents filed by SIGA with the Securities and Exchange Commission, including the SIGA’s annual report on Form 10. -K for the year ended December 31, 2020, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read these documents for free on the SEC’s website at http://www.sec.gov. Interested parties can also obtain these documents free of charge from SIGA. Forward-looking statements are only current as of the date on which such statements were made, and except for our continued obligations under the federal securities laws of the United States of America, we do not undertake not publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
The information in this press release does not necessarily reflect the position or policy of the government and no official endorsement should be inferred.
Laine Yonker, Edison Group
Michael Crawford, Edison Group